Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales increased for both research reagents and equipment. Operating profit was affected by higher selling, general and administrative expenses, primarily due to an increase in personnel expenses.
There are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥8,386 million (YoY +6.4%) |
| Operating profit | ¥255 million (YoY -7.4%) |
| Ordinary income | ¥316 million (YoY -14.5%) |
| Profit attributable to owners of the parent | ¥265 million (YoY -2.8%) |
| Net income per share | ¥46.65 |
| Equity ratio | End of the current fiscal period 76.3 / End of previous period 74 |
| Total assets | ¥12,184 million |
| Net assets | ¥9,891 million |
| Full-year earnings forecast | Net Sales ¥11,500 million (YoY +6.8%) / Operating profit ¥270 million (YoY -21.3%) / Ordinary income ¥380 million (YoY -22.4%) / Net income ¥320 million (YoY -5.1%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥50 → ¥50（0.0%） |
| Depreciation and amortization | ¥139 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sales of investment securities ¥70 million / Extraordinary loss Loss on valuation of investment securities ¥1 million |
| Disclosure regarding the going concern assumption | There are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 6,048,000 shares |
| Treasury Shares at Period-End | 350,079 shares |
| Factors Behind Changes in Business Performance | Net sales increased for both research reagents and equipment. Operating profit was affected by higher selling, general and administrative expenses, primarily due to an increase in personnel expenses. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Amid challenging market conditions and intense price competition with other companies in the same industry, the decrease in operating profit is attributed to higher selling, general and administrative expenses, primarily personnel expenses. The Company is also working to optimize inventory levels and expedite shipments.